OVID Ovid Therapeutics Forecast, Technical & Fundamental Analysis

OVID's RSI Indicator recovers from overbought zone

The 10-day RSI Indicator for OVID moved out of overbought territory on October 06, 2025. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 27 instances where the indicator moved out of the overbought zone. In of the 27 cases the stock moved lower in the days that followed. This puts the odds of a move down at .

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 54 cases where OVID's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OVID declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

OVID broke above its upper Bollinger Band on October 03, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on September 22, 2025. You may want to consider a long position or call options on OVID as a result. In of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for OVID just turned positive on October 02, 2025. Looking at past instances where OVID's MACD turned positive, the stock continued to rise in of 55 cases over the following month. The odds of a continued upward trend are .

Following a +3 3-day Advance, the price is estimated to grow further. Considering data from situations where OVID advanced for three days, in of 277 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 170 cases where OVID Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.231) is normal, around the industry mean (23.456). P/E Ratio (0.000) is within average values for comparable stocks, (54.341). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.164). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (18.692) is also within normal values, averaging (347.799).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. OVID’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OVID’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.